广泛期小细胞肺癌一线治疗成本效益分析数据集

数据集获取（Figshare）

• 源站标题：Table_3_First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis.docx
• DOI：10.3389/fonc.2020.602185.s004
• 发布日期：2020-12-04
• 文件数：1 个
• 文件总体积：16.61 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_3_First-Line_Durvalumab_Plus_Platinum-Etoposide_Versus_Platinum-Etoposide_for_Extensive-Stage_Small-Cell_Lung_Cancer_A_Cost-Effectiveness_Analysis_docx/13333553

命令行下载

curl -L -o "Table_3_First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analy.docx" "https://ndownloader.figshare.com/files/25685003"

文件清单

• Table_3_First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analy.docx（16.61 KB）

文件总体积 16.61 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundThe aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer.
MethodsThis study established a partition survival model for three health states, metastasis probability, and safety data based on the CASPIAN clinical trial. The health utility value was mainly derived from the published literature. Only direct medical costs were considered. Sensitivity analyses were conducted to assess the robustness of the incremental cost per quality-adjusted life year (QALY).
ResultsDurvalumab plus platinum–etoposide increased QALY by 0.220 compared to that observed with platinum–etoposide only. The cost increased by $78,198.75 and the incremental cost per QALY increased by $355,448.86. One-way and probability sensitivity analyses indicated that the model parameters varied within a limited range and had no significant effect on the results.
ConclusionsAlthough durvalumab plus platinum–etoposide can improve quality of life, it also substantially increases the cost of medical treatment. Under a willingness-to-pay threshold of $100,000, durvalumab does not have a cost-effective comparative advantage.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2020.602185.s004（source: https://frontiersin.figshare.com/articles/dataset/Table_3_First-Line_Durvalumab_Plus_Platinum-Etoposide_Versus_Platinum-Etoposide_for_Extensive-Stage_Small-Cell_Lung_Cancer_A_Cost-Effectiveness_Analysis_docx/13333553）。